You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The coalition includes partners from all over the world, including universities, research centers, and health systems in South Asia, Africa, South America, and the US.
Roche Diagnostics CEO Thomas Schinecker said the infrastructure put in place due to the pandemic will allow for more diagnostic testing globally.
Prequalification from the World Health Organization indicates that products meet high quality standards and are safe for their intended use.
DiaSorin got the green light for its Liaison Anti-HAV chemiluminescent immunoassay to detect total antibodies to the hepatitis A virus.
The firm's molecular solutions revenues increased 79 percent to $31.7 million due to COVID-19 testing demand.
Qiagen has benefited from unexpected tailwinds due to COVID-19 testing and envisions post-pandemic growth with recently acquired NeuMoDx as a key contributor.
The tests run on the firm's Liaison XL chemiluminescent immunoassay platform and complete its hepatitis menu in the US.
The PCR test detects HIV-1 RNA on the NeuMoDx 96/288 Molecular Systems and joins the company's other bloodborne viral tests for hepatitis B and C.
The test will be included in the World Health Organizations list of prequalified in vitro diagnostics and UN agencies will be able to procure it.
While the Lab 2.0 vision is still in its early days, a number of outfits around the country are providing examples of how it might be implemented.